Literature DB >> 110603

Renin, aldosterone and renal haemodynamics in cirrhosis with ascites.

V Arroyo, J Bosch, M Mauri, J Viver, A Mas, F Rivera, J Rodes.   

Abstract

The interrelationships between the renin-angiotensin-aldosterone system, renal haemodynamics and urinary sodium excretion were investigated in fifty-six non-azotaemic cirrhotics with ascites. In twelve additional patients the renal renin secretion rate was also studied. Plasma renin activity and concentration and plasma aldosterone ranged from normal to very high values. There was a significant inverse relationship between plasma aldosterone and the urinary sodium excretion. Plasma aldosterone showed a highly significant direct correlation with plasma renin activity, and plasma renin concentration was closely and directly related to the estimated renin secretion rate. Neither plasma renin activity, plasma renin concnetration nor the estimated renin secretion rate correlated with the renal plasma flow or the glomerular filtration rate. These results suggest that in non-azotaemic cirrhosis with ascites the renin-angiotensin-aldosterone system is an important factor influencing sodium excretion, increased plasma renin and aldosterone concentrations are mainly due to an increased secretion rate, and total renal perfusion is not a major factor influencing renin secretion.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 110603     DOI: 10.1111/j.1365-2362.1979.tb01669.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  15 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

2.  Hepatorenal syndrome.

Authors:  Bimaljit Singh Sandhu; Arun J Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

Review 3.  Pathogenesis of ascites and hepatorenal syndrome.

Authors:  S P Wilkinson; K P Moore; V Arroyo
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  Treatment of ascites in patients with cirrhosis of the liver.

Authors:  V Arroyo; P Ginés; J Rodés
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

5.  Renal sodium retention in liver disease.

Authors: 
Journal:  West J Med       Date:  1983-06

6.  Relation between severity of liver disease and renal oxygen consumption in patients with cirrhosis.

Authors:  A Gadano; R Moreau; J Heller; C Chagneau; F Vachiéry; C Trombino; A Elman; C Denié; D Valla; D Lebrec
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

7.  Effect of captopril on renin and blood pressure in cirrhosis.

Authors:  B Stanek; F Renner; A Sedlmayer; K Silberbauer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.

Authors:  Hiroyuki Nakanishi; Masayuki Kurosaki; Takanori Hosokawa; Yuka Takahashi; Jun Itakura; Shoko Suzuki; Yutaka Yasui; Nobuharu Tamaki; Natsuko Nakakuki; Hitomi Takada; Mayu Higuchi; Yasuyuki Komiyama; Tsubasa Yoshida; Kenta Takaura; Tsuguru Hayashi; Konomi Kuwabara; Sei Sasaki; Namiki Izumi
Journal:  J Gastroenterol       Date:  2015-11-26       Impact factor: 7.527

9.  Clinical significance of plasma endothelin-1 in patients with chronic liver disease.

Authors:  H Matsumoto; J Uemasu; M Kitano; H Kawasaki
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

10.  Factors that determine refractoriness of ascites to conventional therapy.

Authors:  S Amra; R Elie; I Kronborg
Journal:  CMAJ       Date:  1986-09-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.